Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Pneumococcal Vaccination | Research

Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany

Authors: Arijita Deb, Bélène Podmore, Rosemarie Barnett, Dominik Beier, Wolfgang Galetzka, Nawab Qizilbash, Dennis Haeckl, Timo Boellinger, Kelly D. Johnson, Thomas Weiss

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16–59 years in Germany who were recommended to receive pneumococcal vaccination, according to STIKO.

Methods

A retrospective cohort analysis was conducted using the German InGef database. Individuals aged 16 to 59 years diagnosed with at least one “at-risk” (chronic disease) or “high-risk” (e.g., immunocompromising) condition considered to be at-risk of pneumococcal infection were identified at the time of first diagnosis, between January 1, 2016 and December 31, 2018, and followed up until December 31, 2019. The percentage of cumulative pneumococcal VCR with 95% confidence interval (CI) was reported for each calendar year of follow-up.

Results

There were 334,292 individuals followed for a median of 2.38 (interquartile range (IQR) 1.63–3.13) person years. For individuals aged 16–59 years diagnosed with an incident risk condition in 2016, pneumococcal VCR increased from 0.44% (95% CI 0.41–0.48) in 2016 to 1.24% (95% CI 1.18–1.30) in 2019. In 2019, VCRs were higher in individuals with high-risk conditions compared with at-risk conditions (2.24% (95% CI 2.09–2.40) vs. 0.90% (95% CI 0.85–0.96)). In 2019, VCRs were higher in individuals aged 50 to 59 years compared with individuals aged 16 to 49 years (2.25% (95% CI 2.10–2.41) vs. 0.90% (95% CI 0.84–0.96)). Similar trends were observed in individuals with newly diagnosed risk conditions identified in 2017 and in 2018. Older age, influenza vaccination and increasing number of risk conditions increased the likelihood of pneumococcal vaccination. Median time to vaccination from diagnosis of the risk condition was shorter for high-risk conditions (369.5 days (IQR 155.8–702.0)) compared to at-risk conditions (435.5 days (IQR 196.3–758.8)).

Conclusion

Despite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16–59 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16–59 years of age developing conditions with higher susceptibility to pneumococcal infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pelton SI, Shea KM, Farkouh RA, Strutton DR, Braun S, Jacob C, Klok R, Gruen ES, Weycker D. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015;15:470.CrossRef Pelton SI, Shea KM, Farkouh RA, Strutton DR, Braun S, Jacob C, Klok R, Gruen ES, Weycker D. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015;15:470.CrossRef
2.
go back to reference Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorac Surg Clin. 2012;67(1):71–9. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorac Surg Clin. 2012;67(1):71–9.
3.
go back to reference Willem L, Blommaert A, Hanquet G, Thiry N, Bilcke J, Theeten H, Verhaegen J, Goossens H, Beutels P. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Hum Vacc Immunothera. 2018;14(5):1218–29.CrossRef Willem L, Blommaert A, Hanquet G, Thiry N, Bilcke J, Theeten H, Verhaegen J, Goossens H, Beutels P. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Hum Vacc Immunothera. 2018;14(5):1218–29.CrossRef
4.
go back to reference Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorac Surg Clin. 2013;68(11):1057–65. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorac Surg Clin. 2013;68(11):1057–65.
5.
go back to reference World Health Organization (WHO). Global status report on noncommunicable diseases. 2020: World Health Organization; 2020. World Health Organization (WHO). Global status report on noncommunicable diseases. 2020: World Health Organization; 2020.
6.
go back to reference Institute for Health Metrics and Evaluation (IHME). Findings from the global burden of disease study 2017. The Lancet. 2018. Institute for Health Metrics and Evaluation (IHME). Findings from the global burden of disease study 2017. The Lancet. 2018.
7.
go back to reference German Standing Committee on Vaccination at the Robert Koch Institute. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute-2017/2018. Epidemiol Bull. 2017: 34. German Standing Committee on Vaccination at the Robert Koch Institute. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute-2017/2018. Epidemiol Bull. 2017: 34.
8.
go back to reference Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014;31(10):1011–44.CrossRef Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014;31(10):1011–44.CrossRef
9.
go back to reference German Standing Committee on Vaccination at the Robert Koch Institute. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute-2016/2017. Epidemiol Bull. 2016; 34. German Standing Committee on Vaccination at the Robert Koch Institute. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute-2016/2017. Epidemiol Bull. 2016; 34.
10.
go back to reference Theidel U, Kuhlmann A, Braem A. Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850 000 individuals. Dtsch Arztebl Int. 2013;110(44):743–50.PubMedPubMedCentral Theidel U, Kuhlmann A, Braem A. Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850 000 individuals. Dtsch Arztebl Int. 2013;110(44):743–50.PubMedPubMedCentral
11.
go back to reference Schmedt N, Schiffner-Rohe J, Sprenger R, Walker J, von Eiff C, Häckl D. Pneumococcal vaccination rates in immunocompromised patients—a cohort study based on claims data from more than 200,000 patients in Germany. PLoS ONE. 2019;14(8):e0220848.CrossRef Schmedt N, Schiffner-Rohe J, Sprenger R, Walker J, von Eiff C, Häckl D. Pneumococcal vaccination rates in immunocompromised patients—a cohort study based on claims data from more than 200,000 patients in Germany. PLoS ONE. 2019;14(8):e0220848.CrossRef
12.
go back to reference Sprenger R, Häckl D, Kossack N, Schiffner-Rohe J, Wohlleben J, von Eiff C. Pneumococcal vaccination rates in immunocompromised patients in Germany: a retrospective cohort study to assess sequential vaccination rates and changes over time. PLoS ONE. 2022;17(3):e0265433.CrossRef Sprenger R, Häckl D, Kossack N, Schiffner-Rohe J, Wohlleben J, von Eiff C. Pneumococcal vaccination rates in immunocompromised patients in Germany: a retrospective cohort study to assess sequential vaccination rates and changes over time. PLoS ONE. 2022;17(3):e0265433.CrossRef
13.
go back to reference Bothe T, Walker J, Kröger C. Gender-related differences in health-care and economic costs for eating disorders: a comparative cost-development analysis for anorexia and bulimia nervosa based on anonymized claims data. Int J Eat Disord. 2021. Bothe T, Walker J, Kröger C. Gender-related differences in health-care and economic costs for eating disorders: a comparative cost-development analysis for anorexia and bulimia nervosa based on anonymized claims data. Int J Eat Disord. 2021.
14.
go back to reference Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf. 2016;25(1):106–9.CrossRef Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf. 2016;25(1):106–9.CrossRef
15.
go back to reference Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR. Cross-sectional study on influenza vaccination, Germany, 1999–2000. Emerg Infect Dis. 2002;8(12):1442–7.CrossRef Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR. Cross-sectional study on influenza vaccination, Germany, 1999–2000. Emerg Infect Dis. 2002;8(12):1442–7.CrossRef
16.
go back to reference Kornum JB, Thomsen RW, Riis A, Lervang H-H, Schønheyder HC, Sørensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541–5.CrossRef Kornum JB, Thomsen RW, Riis A, Lervang H-H, Schønheyder HC, Sørensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541–5.CrossRef
17.
go back to reference van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24.CrossRef van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24.CrossRef
18.
go back to reference Public Health England. Pneumococcal: the Green book of immunisation, Chap. 25. 2020. Public Health England. Pneumococcal: the Green book of immunisation, Chap. 25. 2020.
19.
go back to reference Matthews I, Lu X, Xia Q, Black W, Nozad B. Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis. BMC Public Health. 2020;20(1):1584.CrossRef Matthews I, Lu X, Xia Q, Black W, Nozad B. Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis. BMC Public Health. 2020;20(1):1584.CrossRef
20.
go back to reference Neufeind J, Betsch C, Habersaat KB, Eckardt M, Schmid P, Wichmann O. Barriers and drivers to adult vaccination among family physicians—insights for tailoring the immunization program in Germany. Vaccine. 2020;38(27):4252–62.CrossRef Neufeind J, Betsch C, Habersaat KB, Eckardt M, Schmid P, Wichmann O. Barriers and drivers to adult vaccination among family physicians—insights for tailoring the immunization program in Germany. Vaccine. 2020;38(27):4252–62.CrossRef
21.
go back to reference Klett-Tammen CJ, Krause G, von Lengerke T, Castell S. Advising vaccinations for the elderly: a cross-sectional survey on differences between general practitioners and physician assistants in Germany. BMC Fam Pract. 2016;17(1):98.CrossRef Klett-Tammen CJ, Krause G, von Lengerke T, Castell S. Advising vaccinations for the elderly: a cross-sectional survey on differences between general practitioners and physician assistants in Germany. BMC Fam Pract. 2016;17(1):98.CrossRef
24.
go back to reference Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57–62.CrossRef Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57–62.CrossRef
25.
go back to reference Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother. 2014;10(6):1729–33.CrossRef Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother. 2014;10(6):1729–33.CrossRef
Metadata
Title
Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
Authors
Arijita Deb
Bélène Podmore
Rosemarie Barnett
Dominik Beier
Wolfgang Galetzka
Nawab Qizilbash
Dennis Haeckl
Timo Boellinger
Kelly D. Johnson
Thomas Weiss
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07736-1

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.